History and development
=======================

In an era of anticoagulation development, more options mean more uncertainty. It is imperative for physicians and surgeons to be aware of the available anticoagulation medication, their licenses, dosing and indications. Familiarity with the systemic effects, bleeding risks and reversal options during the pre-, peri- and postoperative periods is of particular importance to surgeons.

Vitamin K antagonists (VKAs) have long been the preferred choice of anticoagulation, but their unpredictable effects, delayed onset of action and need for routine monitoring make them a challenging medication for clinical practice. The advent of the direct oral anticoagulants (DOACs) has revolutionized patient care, supported by multiple randomized controlled trials (RCTs) and meta-analyses prior to the introduction of routine clinical practice.[@b1-vhrm-13-263]--[@b3-vhrm-13-263]

To date, apixaban, dabigatran, edoxaban and rivaroxaban have gained therapeutic licenses within the UK and USA, and these have been secured on the basis of the RCTs listed in [Table 1](#t1-vhrm-13-263){ref-type="table"}.

Pharmacokinetics
================

Apixaban is an oral factor Xa inhibitor that reversibly and selectively inhibits free and clot bound factor Xa. It has a rapid onset of action, with peak effects at around 1--2 hours post dose, and a half-life of \~12 hours. With predictable pharmacokinetics, apixaban can be administered as a fixed twice daily (BD) regimen, without the need for routine monitoring ([Table 2](#t2-vhrm-13-263){ref-type="table"}).[@b4-vhrm-13-263] Currently available preparations include Eliquis^®^ (Bristol-Myers Squibb Pharmaceuticals Ltd).

Its current licenses include[@b4-vhrm-13-263],[@b5-vhrm-13-263] Prevention of stroke in patients with atrial fibrillation (AF) + one congestive heart failure, hypertension, age \>75 years, diabetes mellitus, stroke (CHADS) risk factor (5 mg BD).Prevention of venous thromboembolism (VTE) in elective hip/knee surgery (2.5 mg BD for 35/12 days, respectively).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) (10 mg BD for 7 days then 5 mg BD).Prophylaxis after recurrent DVT/PE (2.5 mg BD).

Apixaban is eliminated in both urine and feces, with renal excretion accounting for \~27%. Consequently, it does not require renal dosing adjustments until the glomerular filtration rate falls below 30 mL/min. In such cases, a half dose (50%) reduction is advised if the patient is \>80 years or \<60 kg.[@b6-vhrm-13-263]

For patients \<60 kg, a 50% reduction in dose is also recommended if they are again either \>80 years or creatinine clearance (CrCl) is \<30 mL/min.

Although there is no significant data available on dosing in mild hepatic impairment, apixaban should be avoided in patients with moderate-to-severe impairment.

The use of apixaban must be reviewed, however, in those patients taking cytochrome P4503 A4 (CYP3A4) and/or P-glycoprotein (P-GP) inducers (such as carbamazepine, phenytoin and rifampicin) as these medications may increase the risk of stroke and/or embolism. The opposite is consequently true for CYP3A4 and P-GP inhibitors, such as itraconazole, ketoconazole, clarithromycin and human immunodeficiency virus protease inhibitors, which may increase the risk of bleeding when used in conjunction with apixaban.[@b7-vhrm-13-263]

The main RCTs defining the use of apixaban over warfarin have been the ARISTOTLE and AMPLIFY studies.[@b4-vhrm-13-263],[@b5-vhrm-13-263] ARISTOTLE reviewed the rates of stroke, death and bleeding during the use of apixaban (compared with warfarin) in AF-related stroke prevention. AMPLIFY randomized patients into receiving either conventional enoxaparin and warfarin or apixaban when diagnosed with acute VTE. The outcomes of these studies and drug safety profiles are discussed below.

Efficacy in stroke prevention
=============================

It is well known that the prevalence of AF increases with age, witĥ10% of the population over 80 years experiencing symptoms.[@b8-vhrm-13-263] The majority of these patients receive oral anticoagulant medication to reduce their risk of AF-related stroke. Previously prescribed medication has included warfarin or other VKAs, but their unpredictable coagulation profile and drug and food interactions limit their therapeutic use.[@b9-vhrm-13-263]

With the advent of DOACs, multiple RCTs compared the use of warfarin with DOAC medications. The ARISTOTLE trial compared apixaban with warfarin in the management of AF-related stroke, particularly highlighting the rates of stroke, death and bleeding with both medications.[@b5-vhrm-13-263]

For this study 18,201 patients were randomly assigned to either warfarin or 5 mg BD apixaban therapy (2.5 mg BD for dose reduction). Although a small number of participants were lost to follow-up (2.1%), overall results showed that fewer patients experienced symptoms of stroke or embolism on apixaban (1.27% vs 1.60%; *P*=0.01). There was a 49% relative risk reduction in the number of hemorrhagic stroke on apixaban (absolute risk reduction \[ARR\]=0.96%, *P*≤0.001), and an 8% relative risk reduction in ischemic stroke (*P*=0.42). Overall mortality rates were lower (3.5% vs 3.9%, *P*=0.047), and major bleeding was significantly lower at 2% with apixaban compared to just over 3% with warfarin (ARR=1%, *P*\<0.001).[@b10-vhrm-13-263]

Alongside these results, apixaban has also been compared with aspirin therapy alone (AVERROES study). Results have again highlighted a 55% relative risk reduction (ARR=2.1%, *P*\<0.001) in the rate of stroke or systemic embolism, with no increase in the risk of major bleeding (*P*=0.07).[@b11-vhrm-13-263]

Efficacy in the prevention of VTE
=================================

VTE is a significant issue in patients with reduced mobility, particularly after surgery. It is, therefore, important to ensure whether appropriate anticoagulant medication is prescribed to prevent venous thromboembolic disease.[@b12-vhrm-13-263]

ADVANCE-1 and ADVANCE-2 trials were phase III clinical trials that evaluated the use of apixaban following total knee replacement. Both studies were noninferiority trials, where the ADVANCE-1 trial reviewed the use of apixaban 2.5 mg once daily (OD) (1,599 patients) compared with subcutaneous enoxaparin 30 mg BD (1,596 patients), and ADVANCE-2 randomized 1,528 patients to receive apixaban 2.5 mg BD and 1,529 patients to receive subcutaneous enoxaparin 40 mg OD.

Results of both studies highlighted that apixaban was noninferior when compared with enoxaparin with regard to VTE prophylaxis (ARR=9%, *P*\<0.0001), and showed a reduction in the rate of bleeding from 5% to 4% (*P*=0.09).[@b13-vhrm-13-263],[@b14-vhrm-13-263] Although no direct RCTs have been performed for the use of apixaban in the prevention of VTE outside hip and knee surgery, the data shown throughout this article are considered to be strong enough evidence for the use of apixaban for this purpose.[@b13-vhrm-13-263]--[@b15-vhrm-13-263]

Efficacy in the treatment of VTE
================================

VTE has an annual incidence of 1--2 per million population and is commonly linked to immobility (e.g., surgery or flights \>4 hours), coagulation disorders and the oral contraceptive pill.[@b16-vhrm-13-263] Conventional therapy includes initial treatment with enoxaparin and 3--6 months of warfarin therapy dependent on VTE anatomical location. The AMPLIFY study randomized and double blinded patients into conventional treatment or 10 mg apixaban BD for 7 days followed by 5 mg BD for 3 months.[@b4-vhrm-13-263]

Five thousand and four hundred patients were enrolled in the study. Of these, a total of 130 patients experienced further thromboembolic events (2.3% apixaban vs and 2.7% conventional therapy), and a similar percentage in each cohort went on to have a positive diagnosis of PE. Overall bleeding rates were again significantly lower following the use of apixaban (0.6% vs 1.8%), highlighting a clinically relevant overall relative risk reduction of 69% (ARR=1.2%, *P*\<0.001).

Safety
======

Both efficacy and safety are key aspects in the development of new medications. This review highlights the clinical results of apixaban; showing similar efficacy in the treatment of acute thromboembolism, AF-related stroke management and VTE prophylaxis when compared with more conventional therapeutic techniques, but patient safety of any new medication is paramount.

The majority of the safety profiling for apixaban has been derived from the RCT's stated above, for example, ARISTOTLE and AMPLIFY. These studies have confirmed that the use of apixaban (when compared with warfarin) has a significantly lower rate of mortality, reduced incidence of major bleeding events ([Table 3](#t3-vhrm-13-263){ref-type="table"}) and few recordable side effects.[@b1-vhrm-13-263]

Bleeding and bridging
=====================

Reversal agents are currently being trialed, but the only marketed drug at present is idarucizumab (PRAXBIND) for dabigatran.[@b17-vhrm-13-263] Consequently, the same protocol as for major bleeding on warfarin must be adhered to: discontinue the drug, apply manual compression, maintain blood pressure, surgical/radiological intervention if appropriate and replace blood products +/− prothrombin complex concentrate.[@b18-vhrm-13-263]

To bridge a DOAC to enoxaparin, the DOAC should be discontinued and enoxaparin commenced at the same time as the next scheduled DOAC dose. When converting to warfarin, all DOACs should be discontinued when the patients' international normalized ratio is in the therapeutic range. For apixaban, therefore, the medication must be continued until recordable therapeutic levels of warfarin are reached (specific to indication), ensuring full antico-agulation effect.

Conclusion
==========

The DOACs are quickly becoming the preferred treatment in the prevention and management of thromboembolic disease. Apixaban has been shown to be a safe alternative to other oral anticoagulant medications and has a reduced risk of bleeding and stroke when used for AF-related stroke prevention and fewer negative outcomes when used in VTE prophylaxis and treatment ([Table 3](#t3-vhrm-13-263){ref-type="table"}). With a twice daily dosing regimen and no need for routine monitoring, apixaban is a safe and effective alternative to other oral anticoagulant medications.
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###### 

DOAC licenses and associated randomized controlled trials

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  DOAC          Randomized controlled trial                                                      Licensing
  ------------- -------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------
  Rivaroxaban   EINSTEIN DVT (rivaroxaban vs enoxaparin for DVT)[@b19-vhrm-13-263]\              Prevention of VTE in elective hip/knee surgery (10 mg OD for 35/12 days, respectively)\
                EINSTEIN PE (rivaroxaban vs enoxaparin for PE)[@b20-vhrm-13-263]\                Treatment of DVT and PE and prophylaxis after recurrent DVT/PE (15 mg BD for 21 days, then 20 mg OD)\
                ROCKET AF (rivaroxaban vs warfarin for AF)[@b21-vhrm-13-263]                     Stroke prevention in patients with AF + one CHADS~2~ risk factor (20 mg OD)\
                                                                                                 **Prevention of atherothrombotic events in adults after acute coronary syndrome (2.5 mg OD)**

  Dabigatran    RE-COVER (dabigatran vs warfarin for VTE)[@b22-vhrm-13-263]\                     Treatment of DVT or PE after parenteral anticoagulation for 5--10 days (150 mg BD)\
                RE-LY (dabigatran vs warfarin in AF)[@b2-vhrm-13-263]                            Stroke prevention in patients with AF + one of reduced ejection fraction/CHD/diabetes/\<65 (150 mg BD)\
                                                                                                 **Prevention of VTE in elective hip/knee surgery (110 mg 1--4 hours after surgery, then 220 mg OD 9/7)**

  Apixaban      ARISTOTLE (apixaban vs warfarin in AF)[@b5-vhrm-13-263]\                         Stroke prevention in patients with AF + one CHADS~2~ risk factor (5 mg BD)\
                AMPLIFY (apixaban vs enoxaparin followed by warfarin for VTE)[@b4-vhrm-13-263]   Prevention of VTE in elective hip/knee surgery (2.5 mg BD for 35/12 days, respectively)\
                                                                                                 Treatment of DVT and PE (10 mg BD for 7 days, then 5 mg BD), or prophylaxis after recurrent DVT/PE (2.5 mg BD)\
                                                                                                 Prevention of VTE (2.5 mg BD)

  Edoxaban      ENGAGE-AF-TIMI (edoxaban to warfarin in AF)[@b23-vhrm-13-263]\                   Treatment of DVT or PE and prophylaxis after recurrent DVT/PE (60 mg OD)\
                Hokusai VTE (edoxaban to warfarin VTE)[@b24-vhrm-13-263]                         Prevention of stroke and systemic embolic events in patients with AF (60 mg OD)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note**: Bold indicates NICE license without US Food and Drug Administration license.

**Abbreviations**: AF, atrial fibrillation; BD, twice daily; CHADS~2~, congestive heart failure, hypertension, age=75 years, diabetes mellitus, stroke (doubled); CHD, coronary heart disease; DOAC, direct oral anticoagulants; DVT, deep vein thrombosis; NICE, National Institute for Clinical Excellence; OD, once daily; PE, pulmonary embolism; VTE, venous thromboembolism.

###### 

Pharmacokinetics of apixaban

  Mode of action                                                                                       Reversible and selectively inhibits free and clot bound factor Xa
  ---------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Prodrug                                                                                              No
  Half-life                                                                                            12 hours
  Peak levels                                                                                          1--2 hours
  Doses                                                                                                BD
  Excretion                                                                                            25% renal
  Use in pregnancy/breast feeding                                                                      No
  Interactions                                                                                         CYP3A4 and P-GP inducers: carbamazepine, phenytoin and rifampicin -- increases risk of stroke/embolism
  CYP3A4 and P-GP inhibitors: HIV protease inhibitors, itraconazole, ketoconazole and clarithromycin   
  CrCl 15--29 mL/min                                                                                   (+Age \>80 OR weight \>60 kg) reduced dose (50%)
  CrCl \<15 mL/min                                                                                     Not indicated
  Weight \<60 kg                                                                                       (+Age \>80 years or CrCl 15--29 mL/min) reduced dose (50%)
  Mild hepatic impairment                                                                              Reduced dose
  Moderate-to-severe hepatic impairment                                                                Not indicated

**Abbreviations**: BD, twice daily; CrCl, creatinine clearance; CYP3A4, cytochrome P450 3A4; HIV; human immunodeficiency virus; P-GP, P-glycoprotein.

###### 

Comparison of the major studies reviewed in the licensing of apixaban

  Study                         Comparison                                                                                Apixaban dose                                       Outcomes                                            Bleeding events              Mortality
  ----------------------------- ----------------------------------------------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ---------------------------- -------------------------------
  ARISTOTLE[@b5-vhrm-13-263]    Apixaban vs warfarin for stroke prevention in AF (18,201 patients)                        5 mg BD                                             Reduced rates of stroke and/or embolism (RR=0.79)   Reduced bleeding (RR=0.67)   Reduced death rates (RR=0.89)
  AMPLIFY[@b4-vhrm-13-263]      Apixaban vs enoxaparin followed by warfarin for treatment of VTE (5,400 patients)         10 mg OD for 7 days followed by 5 mg for 3 months   Noninferior                                         Reduced bleeding (RR=0.33)   N/A
  AVERROES[@b11-vhrm-13-263]    Apixaban vs aspirin for stroke prevention in AF (5,599 patients)                          5 mg BD                                             Reduced rates of stroke and embolism (RR=0.43)      Noninferior                  Reduction (RR=0.80)
  ADVANCE-1[@b13-vhrm-13-263]   Apixaban vs enoxaparin for VTE prophylaxis post total knee replacement (3,195 patients)   2.5 mg BD                                           Noninferior                                         Reduced                      N/A
  ADVANCE-2[@b14-vhrm-13-263]   Apixaban vs enoxaparin for VTE prophylaxis post total knee replacement (3,057 patients)   2.5 mg BD                                           Reduced rates of VTE (RR 0.62)                      Reduced                      N/A

**Abbreviations**: AF, atrial fibrillation; BD, twice daily; OD, once daily; VTE, venous thromboembolism; RR, relative risk; N/A, not available.
